 
        
        
        Periplocin是一种强心甾体,从角果藤(Periploca forrestii)中分离得到,能够促进肿瘤细胞凋亡并抑制肿瘤生长。Periplocin还通过激活Na/K-ATP酶介导的Src/ERK和PI3K/Akt通路,具有促进伤口愈合的潜力。
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 描述 | Periplocin (PP) is a cardiotonic steroid isolated from Periploca forrestii (PF). Periplocin is the highest level of cardiotonic steroid included in PF. Periplocin has the potential to facilitate wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase. Periplocin (5 - 20 μM; 48 hours; L929 cells) treatment shows increased proliferation up to 131% at 20 μM. It increases phosphorylation of Src, ERK, PI3K and Akt at active sites in a dosedependent and time-dependent manner. Periplocin (5 - 20 μM; 48 hours) significantly promotes migration of fibroblast cell and increases collagen production in L929 fibroblast. Periplocin induces Na/KATPase mediates the activation of Src/ERK and PI3K/Akt pathways[1]. In addition, intraperitoneal injection (IP) of periplocin repressed the growth of hepatocellular carcinoma (HCC) in xenograft tumor model in mice[2]. Periplocin inhibits the proliferation of gastric cancer cells and induces apoptosis in vitro and in vivo, indicating its potential to be used as an antitumor drug[3]. Periplocin led to growth inhibition and apoptosis induction by changing the expression of death receptors and inducing DNA double strand breaks in SW-872 cells[4]. | 
| Concentration | Treated Time | Description | References | |
| NCM460 | 44.95 ± 3.59 μM | 24 h | NCM460 cells showed higher tolerance to periplocin | Autophagy. 2023 Dec;19(12):3132-3150. | 
| RKO | 0.12 μM to 0.82 μM | 24 h | Periplocin significantly inhibited CRC cell growth and induced apoptosis | Autophagy. 2023 Dec;19(12):3132-3150. | 
| LOVO | 0.12 μM to 0.82 μM | 24 h | Periplocin significantly inhibited CRC cell growth and induced apoptosis | Autophagy. 2023 Dec;19(12):3132-3150. | 
| HT29 | 0.12 μM to 0.82 μM | 24 h | Periplocin significantly inhibited CRC cell growth and induced apoptosis | Autophagy. 2023 Dec;19(12):3132-3150. | 
| SW620 | 0.12 μM to 0.82 μM | 24 h | Periplocin significantly inhibited CRC cell growth and induced apoptosis | Autophagy. 2023 Dec;19(12):3132-3150. | 
| HCT116 | 0.12 μM to 0.82 μM | 24 h | Periplocin significantly inhibited CRC cell growth and induced apoptosis | Autophagy. 2023 Dec;19(12):3132-3150. | 
| SW480 | 0.12 μM to 0.82 μM | 24 h | Periplocin significantly inhibited CRC cell growth and induced apoptosis | Autophagy. 2023 Dec;19(12):3132-3150. | 
| DLD-1 | 0.12 μM to 0.82 μM | 24 h | Periplocin significantly inhibited CRC cell growth and induced apoptosis | Autophagy. 2023 Dec;19(12):3132-3150. | 
| KYSE-150 | 50, 100, 200 ng/ml | 24 h and 48 h | CPP alone or in combination with TRAIL could inhibit the proliferation of ESCC cells and induce apoptosis. | J Exp Clin Cancer Res. 2019 Dec 21;38(1):501. | 
| YES-2 | 50, 100, 200 ng/ml | 24 h and 48 h | CPP alone or in combination with TRAIL could inhibit the proliferation of ESCC cells and induce apoptosis. | J Exp Clin Cancer Res. 2019 Dec 21;38(1):501. | 
| Eca-109 | 50, 100, 200 ng/ml | 24 h and 48 h | CPP alone or in combination with TRAIL could inhibit the proliferation of ESCC cells and induce apoptosis. | J Exp Clin Cancer Res. 2019 Dec 21;38(1):501. | 
| Peripheral blood lymphocytes (PBLs) | 50, 100, 200, 400 ng/mL | 72 h | Periplocin had no effect on the proliferation of PBLs | Drug Des Devel Ther. 2021 Mar 26;15:1333-1344. | 
| Jurkat cells | 50, 100, 200, 400 ng/mL | 24, 48, 72 h | Periplocin significantly inhibited the proliferation of Jurkat cells in a dose- and time-dependent manner | Drug Des Devel Ther. 2021 Mar 26;15:1333-1344. | 
| HuT 78 cells | 50, 100, 200, 400 ng/mL | 24, 48, 72 h | Periplocin significantly inhibited the proliferation of HuT 78 cells in a dose- and time-dependent manner | Drug Des Devel Ther. 2021 Mar 26;15:1333-1344. | 
| MDCK-MDR1 cells | 75 µM and 100 µM | 120 min | Evaluate the permeability of Periplocin in MDCK-MDR1 cells, showing that P-gp is involved in the transport of Periplocin. | Drug Des Devel Ther. 2014 May 9;8:475-83. | 
| MDCK cells | 75 µM and 100 µM | 120 min | Evaluate the permeability of Periplocin in MDCK cells, showing that Periplocin has weak permeability. | Drug Des Devel Ther. 2014 May 9;8:475-83. | 
| Administration | Dosage | Frequency | Description | References | ||
| Nude mice | SW480 xenograft model | Intraperitoneal injection | 15 mg/kg | Once daily for two weeks | Periplocin significantly inhibited the growth of CRC xenografts with minimal toxicity | Autophagy. 2023 Dec;19(12):3132-3150. | 
| BALB/c nude mice | ESCC xenografted tumor | Intraperitoneal injection | 0.09 mg and 0.36 mg | Every two days for 14 days | CPP alone or in combination with TRAIL showed significant anti-tumor activity in vivo. | J Exp Clin Cancer Res. 2019 Dec 21;38(1):501. | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 1.44mL 0.29mL 0.14mL | 7.18mL 1.44mL 0.72mL | 14.35mL 2.87mL 1.44mL | |
| CAS号 | 13137-64-9 | 
| 分子式 | C36H56O13 | 
| 分子量 | 696.82 | 
| SMILES Code | O=C1OCC([C@H]2CC[C@]3(O)[C@]4([H])CC[C@]5(O)C[C@@H](O[C@H]6C[C@H](OC)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](C)O6)CC[C@]5(C)[C@@]4([H])CC[C@]23C)=C1 | 
| MDL No. | MFCD01745141 | 
| 别名 | Periplocoside | 
| 运输 | 蓝冰 | 
| InChI Key | KWBPKUMWVXUSCA-AXQDKOMKSA-N | 
| Pubchem ID | 14463159 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, 2-8°C | 
| 溶解方案 | DMSO: 105 mg/mL(150.68 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1